目錄:MedChemExpress LLC>>信號通路>> Ixabepilone | 伊沙匹隆 | MedChemExpress (MCE)
CAS | 219989-84-1 | 純度 | 99.93% |
---|---|---|---|
分子量 | 506.7 | 分子式 | C??H??N?O?S |
供貨周期 | 現貨 | 規格 | 10 mM * 1 mL |
貨號 | HY-10222 | 應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 219989-84-1
MCE 國際站:Ixabepilone
產品活性:Ixabepilone (BMS-247550) 是一種可口服的 microtubule抑制劑,能夠與微管蛋白結合,促進微管蛋白的聚合和微管的穩定,因此使細胞停滯在 G2-M 期,誘導細胞凋亡。
研究領域:Cell Cycle/DNA Damage | Cytoskeleton | Apoptosis | Anti-infection
作用靶點:Microtubule/Tubulin | Apoptosis | Bacterial
In Vitro: BMS-247550 is a highly potent cytotoxic agent capable of killing cancer cells at low nanomolar concentrations and retains its antineoplastic activity against human cancers that are naturally insensitive to paclitaxel or that have developed resistance to paclitaxel.
In Vivo: BMS-247550 demonstrates antitumor activity that is superior to paclitaxel in both paclitaxel-resistant and -sensitive tumors. BMS-247550 is more efficacious than paclitaxel in all five paclitaxel-resistant tumors evaluated in this study (four human and one murine): the clinically derived paclitaxel resistant Pat-7 ovarian carcinoma, the A2780Tax ovarian carcinoma that is resistant to paclitaxel because of tubulin mutations, the HCT116/VM46 MDR colon carcinoma, the clinically derived paclitaxel-resistant Pat-21 breast carcinoma, and the murine fibrosarcoma M5076. Against three paclitaxel-sensitive human tumor xenografts, BMS-247550 produces antitumor activity equivalent to paclitaxel: A2780 human ovarian carcinoma, HCT116, and LS174T human colon carcinoma.
相關產品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Antibacterial Compound Library | Cytoskeleton Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Lung Cancer Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Targeted Diversity Library | Protein-protein Interaction Inhibitor Library | Chemotherapy Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Off-patent Drug Library | Cell Death Library | MG-132 | Rapamycin | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Dexamethasone | Acetylcysteine | Puromycin dihydrochloride | Angiotensin II human | Dimethyl sulfoxide | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | G-418 disulfate | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds